Search

Your search keyword '"Lassalle R"' showing total 406 results
Start Over Author "Lassalle R"
406 results on '"Lassalle R"'

3. Évaluation du risque d’événements thrombo-emboliques, d’événements cardiovasculaires graves et d'infection graves chez les patients atteints de polyarthrite rhumatoïde traités par baricitinib versus anti-TNF en France

Author

Thurin, N.H., primary, Polinski, J., additional, Grelaud, A., additional, Bernard, M-A., additional, Grolleau, A., additional, Bignon, E., additional, Lassalle, R., additional, Blin, P., additional, and Droz-Perroteau, C., additional

Published
2023
Full Text
View/download PDF

4. Cardiovascular or renal disease (CVRD) complication and mortality incidence for type 2 diabetics with a single or without CVRD comorbidity: A 5-year SNDS nationwide claims database cohort study

Author

Jourdain, P., primary, Blin, P., additional, Zaoui, P., additional, Guiard, E., additional, Sakr, D., additional, Bernard, M.-A., additional, Dureau-Pournin, C., additional, Lassalle, R., additional, Thomas-Delecourt, F., additional, Bineau, S., additional, Moore, N., additional, Droz-Perroteau, C., additional, and Joubert, M., additional

Published
2023
Full Text
View/download PDF

6. EE600 Cumulative Cardiovascular or Renal Disease (CVRD) Hospital Costs for Type 2 Diabetics Free of CVRD at Baseline: A 5-Year Cohort Study in the SNDS Nationwide Claims Database

Author

Blin, P, primary, Zaoui, P, additional, Joubert, M, additional, Guiard, E, additional, Sakr, D, additional, Dureau-Pournin, C, additional, Bernard, MA, additional, Lassalle, R, additional, Thomas-Delecourt, F, additional, Bineau, S, additional, Moore, N, additional, Droz-Perroteau, C, additional, and Jourdain, P, additional

Published
2022
Full Text
View/download PDF

9. Cardiovascular or renal disease (CVRD) complication and mortality incidence for type 2 diabetics with a single or without CVRD comorbidity: a 5-year SNDS nationwide claims database cohort study

Author

Jourdain, P, primary, Blin, P, additional, Zaoui, P, additional, Guiard, E, additional, Sakr, D, additional, Dureau-Pournin, C, additional, Bernard, M A, additional, Lassalle, R, additional, Thomas-Delecourt, F, additional, Bineau, S, additional, Moore, N, additional, Droz-Perroteau, C, additional, and Joubert, M A, additional

Published
2022
Full Text
View/download PDF

14. Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008–2015)

Author

Sabaté, M., primary, Vidal, X., additional, Ballarin, E., additional, Rottenkolber, M., additional, Schmiedl, S., additional, Grave, B., additional, Huerta, C., additional, Martin-Merino, E., additional, Montero, D., additional, Leon-Muñoz, L. M., additional, Gasse, C., additional, Moore, N., additional, Droz, C., additional, Lassalle, R., additional, Aakjær, M., additional, Andersen, M., additional, De Bruin, M. L., additional, Souverein, P., additional, Klungel, O. H., additional, Gardarsdottir, H., additional, and Ibáñez, L., additional

Published
2021
Full Text
View/download PDF

16. Contraction criteria for Brownian filtrations samplings

Author

Lassalle, R��mi

Subjects
Probability (math.PR), FOS: Mathematics
Abstract

This paper investigates the problem to determine whether a given stochastic process generates a sampled Brownian filtration. A fairly general sufficient condition is obtained by applying the Frank H. Clarke contraction criteria to a functional whose construction relies on the quasi-invariance properties of a sampled Wiener measure. The latter are investigated from the precise analytic structure underlying this sampled Brownian motion. In particular, the Cameron-Martin space is identified from usual Lebesgue integrals over a Guseinov measure. As an application we obtain sufficient conditions for the existence of a solution to a class of not necessarily Markovian stochastic differential equations driven by a sampled Brownian motion. By taking a sampling times set which coincides with the unit interval, the results apply to continuous time models., This is a working paper

Published
2021
Full Text
View/download PDF

17. Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008-2015)

Author

Sabaté, M, Vidal, X, Ballarin, E, Rottenkolber, M, Schmiedl, S, Grave, B, Huerta, C, Martin-Merino, E, Montero, D, Leon-Muñoz, L M, Gasse, C, Moore, N, Droz, C, Lassalle, R, Aakjær, M, Andersen, M, De Bruin, M L, Souverein, P, Klungel, O H, Gardarsdottir, H, Ibáñez, L, Sabaté, M, Vidal, X, Ballarin, E, Rottenkolber, M, Schmiedl, S, Grave, B, Huerta, C, Martin-Merino, E, Montero, D, Leon-Muñoz, L M, Gasse, C, Moore, N, Droz, C, Lassalle, R, Aakjær, M, Andersen, M, De Bruin, M L, Souverein, P, Klungel, O H, Gardarsdottir, H, and Ibáñez, L

Abstract

Aims: To describe and compare the adherence to different direct oral anticoagulants (DOACs) in eight European databases representing six countries. Methods: Longitudinal drug utilization study of new users (≥18 years) of DOACs (dabigatran, rivaroxaban, apixaban) with a diagnosis of non-valvular atrial fibrillation (2008-2015). Adherence was examined by estimating persistence, switching, and discontinuation rates at 12 months. Primary non-adherence was estimated in BIFAP and SIDIAP databases. Results: The highest persistence rate was seen for apixaban in the CPRD database (81%) and the lowest for dabigatran in the Mondriaan database (22%). The switching rate for all DOACs ranged from 2.4 to 13.1% (Mondriaan and EGB databases, respectively). Dabigatran had the highest switching rate from 5.0 to 20.0% (Mondriaan and EGB databases, respectively). The discontinuation rate for all DOACs ranged from 16.0 to 63.9% (CPRD and Bavarian CD databases, respectively). Dabigatran had the highest rate of discontinuers, except in the Bavarian CD and AOK NORDWEST databases, ranging from 23.2 to 64.6% (CPRD and Mondriaan databases, respectively). Combined primary non-adherence for examined DOACs was 11.1% in BIFAP and 14.0% in SIDIAP. There were differences in population coverage and in the type of drug data source among the databases. Conclusion: Despite the differences in the characteristics of the databases and in demographic and baseline characteristics of the included population that could explain some of the observed discrepancies, we can observe a similar pattern throughout the databases. Apixaban was the DOAC with the highest persistence. Dabigatran had the highest proportion of discontinuers and switchers at 12 months in most databases (EMA/2015/27/PH).

Published
2021

18. Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008-2015)

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Sabaté, M, Vidal, X, Ballarin, E, Rottenkolber, M, Schmiedl, S, Grave, B, Huerta, C, Martin-Merino, E, Montero, D, Leon-Muñoz, L M, Gasse, C, Moore, N, Droz, C, Lassalle, R, Aakjær, M, Andersen, M, De Bruin, M L, Souverein, P, Klungel, O H, Gardarsdottir, H, Ibáñez, L, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Sabaté, M, Vidal, X, Ballarin, E, Rottenkolber, M, Schmiedl, S, Grave, B, Huerta, C, Martin-Merino, E, Montero, D, Leon-Muñoz, L M, Gasse, C, Moore, N, Droz, C, Lassalle, R, Aakjær, M, Andersen, M, De Bruin, M L, Souverein, P, Klungel, O H, Gardarsdottir, H, and Ibáñez, L

Published
2021

19. Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation:A Cross-National Comparison in Six European Countries (2008–2015)

Author

Sabaté, M., Vidal, X., Ballarin, E., Rottenkolber, M., Schmiedl, S., Grave, B., Huerta, C., Martin-Merino, E., Montero, D., Leon-Muñoz, L. M., Gasse, C., Moore, N., Droz, C., Lassalle, R., Aakjær, M., Andersen, M., De Bruin, M. L., Souverein, P., Klungel, O. H., Gardarsdottir, H., Ibáñez, L., Sabaté, M., Vidal, X., Ballarin, E., Rottenkolber, M., Schmiedl, S., Grave, B., Huerta, C., Martin-Merino, E., Montero, D., Leon-Muñoz, L. M., Gasse, C., Moore, N., Droz, C., Lassalle, R., Aakjær, M., Andersen, M., De Bruin, M. L., Souverein, P., Klungel, O. H., Gardarsdottir, H., and Ibáñez, L.

Abstract

Aims: To describe and compare the adherence to different direct oral anticoagulants (DOACs) in eight European databases representing six countries. Methods: Longitudinal drug utilization study of new users (≥18 years) of DOACs (dabigatran, rivaroxaban, apixaban) with a diagnosis of non-valvular atrial fibrillation (2008–2015). Adherence was examined by estimating persistence, switching, and discontinuation rates at 12 months. Primary non-adherence was estimated in BIFAP and SIDIAP databases. Results: The highest persistence rate was seen for apixaban in the CPRD database (81%) and the lowest for dabigatran in the Mondriaan database (22%). The switching rate for all DOACs ranged from 2.4 to 13.1% (Mondriaan and EGB databases, respectively). Dabigatran had the highest switching rate from 5.0 to 20.0% (Mondriaan and EGB databases, respectively). The discontinuation rate for all DOACs ranged from 16.0 to 63.9% (CPRD and Bavarian CD databases, respectively). Dabigatran had the highest rate of discontinuers, except in the Bavarian CD and AOK NORDWEST databases, ranging from 23.2 to 64.6% (CPRD and Mondriaan databases, respectively). Combined primary non-adherence for examined DOACs was 11.1% in BIFAP and 14.0% in SIDIAP. There were differences in population coverage and in the type of drug data source among the databases. Conclusion: Despite the differences in the characteristics of the databases and in demographic and baseline characteristics of the included population that could explain some of the observed discrepancies, we can observe a similar pattern throughout the databases. Apixaban was the DOAC with the highest persistence. Dabigatran had the highest proportion of discontinuers and switchers at 12 months in most databases (EMA/2015/27/PH).

Published
2021

21. Patterns of quadruple therapy use including bismuth for Helicobacter pylori eradication: A cohort study in the French national claims database

Author

Blin, Patrick, Rouyer, Magali, Guiard, Estelle, Zerbib, F., DIQUET, B., MEGRAUD, F., Tison, F., Abouelfath, Abdelilah, Lassalle, R., DROZ-PERROTEAU, Cecile, Moore, Nicholas, Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
surgical procedures, operative, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Abstract

BACKGROUND: Quadruple therapy using a single capsule formulation of bismuth, metronidazole and tetracycline (BMT; Pylera®), associated with omeprazole for the eradication of Helicobacter pylori, represents the reintroduction of bismuth in France after 40 years. OBJECTIVE: To describe the real-life patterns of use of BMT following a request from the French health authorities. METHODS: Patients with a first BMT dispensing (index date, ID), with one year of data before and after ID, were identified in the French nationwide claims database 1/97 sample. Misuse of BMT was defined as dispensing>1 pack of BMT at ID or absence of a diagnostic test in the preceding year. RESULTS: In total, 540 patients were included. Prescribers were gastroenterologists (n=243; 45%) and general practitioners (n=160; 30%). A proton pump inhibitor was co-dispensed to 504 patients (96%). Ten patients (2%) had contraindications to BMT. Fifty-nine patients (11%) met the misuse criteria: ten (2%) were dispensed>1 pack of BMT and 49 (9%) had not had a diagnostic test for H. pylori in the previous year. During follow-up, 27 patients (5%) required retreatment (treatment failure). CONCLUSION: In this real-life study, most patients were dispensed only one pack of BMT, consistent with recommendations. Misuse related principally to the absence of prior diagnostic test for H. pylori.

Published
2020

22. PND25 Cost-Consequence Analysis of Dimethyl Fumarate Versus Other Disease-Modifying Therapies in Multiple Sclerosis: A French Cohort Study with Snds National Claims Database in France

Author

Bosco-Levy, P., primary, Blin, P., additional, Lignot-Maleyran, S., additional, Lassalle, R., additional, Abouelfath, A., additional, Diez, P., additional, Debouverie, M., additional, Brochet, B., additional, Guillemin, F., additional, Moore, N., additional, and Droz-Perroteau, C., additional

Published
2020
Full Text
View/download PDF

24. Real world risk of major outcomes for type 2 diabetes with stable coronary artery disease without prior MI or stroke and THEMIS-like patients using the SNDS French nationwide claims database

Author

Blin, P, primary, Darmon, P, additional, Henry, P, additional, Guiard, E, additional, Bernard, M.-A, additional, Dureau-Pournin, C, additional, Maizi, H, additional, Thomas-Delecourt, F, additional, Lassalle, R, additional, Droz-Perroteau, C, additional, and Moore, N, additional

Published
2020
Full Text
View/download PDF

25. Prevalence of type 2 diabetes with stable coronary artery disease but without prior myocardial infarction or stroke and THEMIS-like patients from the SNDS French nationwide claims database

Author

Blin, P, primary, Darmon, P, additional, Henry, P, additional, Dureau-Pournin, C, additional, Bernard, M.-A, additional, Guiard, E, additional, Maizi, H, additional, Thomas-Delecourt, F, additional, Lassalle, R, additional, Droz-Perroteau, C, additional, and Moore, N, additional

Published
2020
Full Text
View/download PDF

26. Comparaison du bénéfice-risque à trois ans du dabigatran versus rivaroxaban, en fonction de la dose standard ou réduite, dans la fibrillation auriculaire non-valvulaire, cohorte ENGEL 2 à partir des données du Système national des données de santé avec appariement sur un score de propension haute dimension

Author

Blin, P., primary, Cottin, Y., additional, Dureau-Pournin, C., additional, Abouelfath, A., additional, Lassalle, R., additional, Guiard, E., additional, Balestra, A., additional, Mismetti, P., additional, de Pouvourville, G., additional, Droz-Perroteau, C., additional, Benichou, J., additional, and Moore, N., additional

Published
2020
Full Text
View/download PDF

27. Efficacité en vie réelle de diméthylfumarate dans la sclérose en plaques : cohorte à partir des données du Système national des données de santé

Author

Bosco-Levy, P., primary, Blin, P., additional, Lignot-Maleyran, S., additional, Lassalle, R., additional, Abouelfath, A., additional, Diez-Andreu, P., additional, Debouverie, M., additional, Brochet, B., additional, Guillemin, F., additional, Moore, N., additional, and Droz-Perroteau, C., additional

Published
2020
Full Text
View/download PDF

28. Validation d’un algorithme complexe d’identification de poussées dans la sclérose en plaque à partir du Système national des données de santé

Author

Bosco-Levy, P., primary, Blin, P., additional, Lignot-Maleyran, S., additional, Lassalle, R., additional, Abouelfath, A., additional, Diez-Andreu, P., additional, Debouverie, M., additional, Brochet, B., additional, Louapre, C., additional, Heinzlef, O., additional, Maillart, E., additional, Moore, N., additional, and Droz-Perroteau, C., additional

Published
2020
Full Text
View/download PDF

33. Therapie

Author

BENARD-LARIBIERE, Anne, NOIZE, Pernelle, GIRODET, P. O., LASSALLE, R., DUREAU-POURNIN, C., DROZ-PERROTEAU, C., FOURRIER-REGLAT, Annie, SALVO, Francesco, BEZIN, Julien, and PARIENTE, Antoine

Published
2019

34. Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study

Author

Gouverneur, Amandine, Coutureau, J., Jove, J., Rouyer, M., Grelaud, A., Duc, S., Gerard, Sébastien, Smith, D., Ravaud, A., Droz, C., Bernard, M. A., Lassalle, R., Forrier-Reglat, Annie, Noize, Pernelle, CCSD, Accord Elsevier, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Pharmacoepidemiologie et évaluation de l'impact des produits de santé sur les populations, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Bordeaux Segalen - Bordeaux 2-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux], and ETNA study group and the EREBUS study group: D Smith, N Tubiana-Mathieu, P Michel, R Guimbaud, Y Becouarn, F Viret, R Guimbaud, D Larregain-Fournier, Y Botreau, P Texereau, D Auby, L Gautier-Felizot, I Loury-Larivière, E Brudieux, L Cany, C Lecaille, D Jaubert, P Guichard, O Bernard, L Vives, N Taoubi, M Martinez, F Burki, I Roque, F Thouveny, M H Gaspard

Subjects
Colorectal neoplasm, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Neoplasm metastasis, Molecular targeted therapy, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Frail elderly, Aged
Abstract

International audience; BACKGROUND: Metastatic colorectal cancer (mCRC) is increasingly treated using targeted therapies. Their real-life evaluation is insufficient, especially in elderly and frail patients. The aim was to describe use, safety, and effectiveness of targeted therapies in first-line mCRC treatment according to age. PATIENTS AND METHODS: Two field cohorts of patients initiating bevacizumab or cetuximab for first-line mCRC were pooled. Patients characteristics, use, and safety were compared between younger and elderly patients (/=75 years). Two-year overall survival (OS) and progression-free survival (PFS) were estimated in both age groups using the Kaplan-Meier method adjusted on factors associated with death or progression identified with Cox multivariate modeling. RESULTS: Eight hundred patients (n = 411, 51.4% bevacizumab) were included: 498 (62.3%) male, median age 64 years, 118 (14.8%) Eastern Cooperative Oncology Group performance status (ECOG-PS) >/=2. Elderly patients (n = 126, 15.8%) were more often treated with 5-fluorouracil alone than younger. Severe adverse events were equivalent across age groups. ECOG-PS >/=1, abnormal hemoglobin, and abnormal alkaline phosphatases were associated with a higher risk of death; OS adjusted on these factors was similar between elderly and younger patients. ECOG-PS >/=1, lung metastases, abnormal hemoglobin, and abnormal creatinine clearance were associated with a higher risk of progression or death; PFS adjusted on these factors was similar across groups. CONCLUSION: Despite treatment adaptations, elderly patients could benefit from targeted therapies as younger without safety warning.

Published
2019

35. Clin Colorectal Cancer

Author

GOUVERNEUR, Amandine, COUTUREAU, J., JOVE, J., ROUYER, M., GRELAUD, A., DUC, S., GERARD, S., SMITH, D., RAVAUD, A., DROZ, C., BERNARD, M. A., LASSALLE, R., FORRIER-REGLAT, Annie, and NOIZE, Pernelle

Published
2019

36. Incidence of Direct Oral Anticoagulant use in patients with non-valvular atrial fibrillation and characteristics of users in six European countries (2008-2015):A cross-national drug utilization study

Author

Ibáñez, L, Sabaté, M, Vidal, X, Ballarin, E, Rottenkolber, M, Schmiedl, S, Heeke, A, Huerta, C, Martin Merino, E, Montero, D, Leon-Muñoz, L M, Gasse, C, Moore, N, Droz, C, Lassalle, R, Aakjaer, M, Andersen, M, De Bruin, M L, Groenwold, R, van den Ham, R, Souverein, P, Klungel, O, and Gardarsdottir, H

Abstract

AIMS: To estimate the incidence of Direct Oral Anticoagulant Drug (DOAC) use in patients with non-valvular atrial fibrillation and to describe user and treatment characteristics in 8 European healthcare databases representing 6 European countries.METHODS: Longitudinal drug utilization study from January 2008 to December 2015. A common protocol approach was applied. Annual period incidences and direct standardisation by age and sex were performed. Dose adjustment related to change in age and by renal function as well as concomitant use of potentially interacting drugs were assessed.RESULTS: A total of 186,405 new DOAC users (≥18 years) were identified. Standardized incidences varied from 1.93-2.60 and 0.11-8.71 users/10,000 (2011-2015) for dabigatran and rivaroxaban, respectively, and from 0.01-8.12 users/10,000 (2012-2015) for apixaban. In 2015, the DOAC incidence ranged from 9 to 28/10,000 inhabitants in SIDIAP (Spain) and DNR (Denmark) respectively. There were differences in population coverage among the databases. Only one database includes the total reference population (DNR) while others are considered a population representative sample (CPRD, BIFAP, SIDIAP, EGB, Mondriaan). They also varied in the type of drug data source (administrative, clinical). Dose adjustment ranged from 4.6% in BIFAP (Spain) to 15.6% in EGB (France). Concomitant use of interacting drugs varied between 16.4% (SIDIAP), and 70.5% (EGB). Cardiovascular comorbidities ranged from 25.4% in Mondriaan (The Netherlands) to 82.9% in AOK Nordwest (Germany).CONCLUSION: Overall, apixaban and rivaroxaban increased its use during the study period while dabigatran decreased. There was variability in patient characteristics such as co-morbidities, potentially interacting drugs and dose adjustment. (EMA/2015/27/PH).

Published
2019

38. Value in Health

Author

BLIN, Patrick, COTTIN, Y., DUREAU-POURNIN, C., ABOUELFATH, A., LASSALLE, R., BENICHOU, Jacques, DE POUVOURVILLE, G., MISMETTI, P., DROZ-PERROTEAU, C., MOORE, Nicholas, Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
PharmacoEpi-Drugs, CIC1401, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Published
2018

39. European Heart Journal

Author

Cottin, Y., Blin, P., Benichou, Jacques, Dureau-Pournin, C., Abouelfath, A., Lassalle, R., Droz-Perroteau, C., Mismetti, P., Moore, Nicholas, Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
PharmacoEpi-Drugs, CIC1401, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Published
2018

40. Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample

Author

Duong, M., Abouelfath, A., Lassalle, R., Droz, C., Blin, P., Moore, Nicholas, Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
PharmacoEpi-Drugs, CIC1401, organic chemicals, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Abstract

INTRODUCTION: Non-steroidal anti-inflammatory drugs are associated with a dose and duration-dependent coronary risk. There is little information concerning analgesic-dose ibuprofen, among the most widely used drugs worldwide. OBJECTIVE: Our objective was to measure the risks of acute coronary syndrome (ACS) after dispensing of ibuprofen, versus paracetamol. METHODS: Propensity score 1:2-matched cohorts of ibuprofen or paracetamol treatment episodes (TEs) in Echantillon Generaliste de Beneficiaires (EGB), the 1/97 sample of Systeme National des Donnees de Sante (SNDS), the French nationwide claims database, from 2009 to 2014, were compared. Outcomes were hospital admissions for ACS during the 3 months after the dispensing of ibuprofen or paracetamol. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated overall and stratified on low-dose aspirin dispensing. RESULTS: A total of 315,269 ibuprofen TEs in 168,400 persons were matched to 630,457 paracetamol TEs in 395,952 patients. Event rates were 50-100 times higher in low-dose aspirin users (27 vs 0.28 per 1000 patient years). Overall there was no difference in risk of ACS at 3 months (HR 0.94, 95% CI 0.74-1.20) despite a transient increase in the first 2 weeks in ibuprofen users (HR 1.70, 95% CI 1.11-2.59). In the stratified analysis, this short-term risk was only found in aspirin users (5% of population, HR 1.84, 95% CI 1.24-3.24), but not in non-aspirin users (HR 1.09, 95% CI 0.40-2.94). CONCLUSIONS: There was no evidence for an increased risk of ACS in patients dispensed ibuprofen compared to paracetamol.

Published
2018

41. PND75 VALIDATION OF AN ALGORITHM IDENTIFYING RELAPSES IN MULTIPLE SCLEROSIS USING THE FRENCH NATIONWIDE CLAIMS DATABASE

Author

Bosco-Levy, P., primary, Blin, P., additional, Lignot-Maleyran, S., additional, Lassalle, R., additional, Abouelfath, A., additional, Diez, P., additional, Debouverie, M., additional, Brochet, B., additional, Louapre, C., additional, Heinzlef, O., additional, Maillart, E., additional, Moore, N., additional, and Droz-Perroteau, C., additional

Published
2019
Full Text
View/download PDF

49. Bénéfice-risque des doses standard et réduite du dabigatran versus rivaroxaban dans la fibrillation auriculaire non valvulaire : cohorte de plus de 55 000 patients issus du Système national des données de santé

Author

Blin, P., primary, Cottin, Y., additional, Dureau-Pournin, C., additional, Abouelfath, A., additional, Lassalle, R., additional, Bénichou, J., additional, de Pouvourville, G., additional, Mismetti, P., additional, and Droz-Perroteau, C., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results